SCHEMBL3093465

SCHEMBL3093465

NC(=O)Oc1ccc(-c2nc3ccc(OCc4c(Cl)cccc4Cl)cc3s2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.51
MAPT P10636 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
THRB P10828 1/20 0.47
CYP2D6 P10635 1/20 0.44
APP P05067 3/20 0.43
SULT1A1 P50225 1/20 0.43
CYP3A4 P08684 2/20 0.42
TP53 P04637 2/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
RORC P51449 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3098705 0.93 NR1H4 (0.48) NR1H4MAPTSMN1; SMN2THRBCYP2D6
SCHEMBL3093410 0.88 APP (0.46) NR1H4MAPTAPPSULT1A1CYP3A4
SCHEMBL3109618 0.85 FFAR1 (0.40) NR1H4MAPTSMN1; SMN2THRBAPP
SCHEMBL3093456 0.85 NR1H4 (0.46) NR1H4MAPTSMN1; SMN2THRBCYP2D6
SCHEMBL3102185 0.83 MAPT (0.45) NR1H4MAPTSMN1; SMN2THRBCYP2D6
SCHEMBL3099137 0.81 APP (0.45) NR1H4MAPTSMN1; SMN2THRBAPP
SCHEMBL3099179 0.81 MAPT (0.43) NR1H4MAPTSMN1; SMN2THRBAPP
SCHEMBL3113138 0.80 APP (0.43) NR1H4MAPTSMN1; SMN2THRBCYP2D6
SCHEMBL3098700 0.80 NR1H4 (0.43) NR1H4SMN1; SMN2TP53KDM4EMEN1
SCHEMBL3093478 0.79 APP (0.41) NR1H4MAPTSMN1; SMN2THRBAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 NR1H4 710/4885MAPT 2894/4885SMN1; SMN2 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.